Related references
Note: Only part of the references are listed.Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
Joao Pedro Ferreira et al.
AMERICAN JOURNAL OF HYPERTENSION (2020)
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Kieran F. Docherty et al.
EUROPEAN HEART JOURNAL (2020)
Omics phenotyping in heart failure: the next frontier
Antoni Bayes-Genis et al.
EUROPEAN HEART JOURNAL (2020)
Estimating lifetime benefits of comprehensive disease -modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Muthiah Vaduganathan et al.
LANCET (2020)
Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial A Secondary Analysis of a Randomized Clinical Trial
Mona Fiuzat et al.
JAMA CARDIOLOGY (2020)
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Paul W. Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Streamlining and Reimagining Prior Authorization Under Value-Based Contracts: A Call to Action From the Value in Healthcare Initiative's Prior Authorization Learning Collaborative
Mitchell A. Psotka et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)
Risk Profiles in Heart Failure Baseline, Residual, Worsening, and Advanced Heart Failure Risk
Stephen J. Greene et al.
CIRCULATION-HEART FAILURE (2020)
Proteomic Signatures During Treatment in Different Stages of Heart Failure
Sam A. Michelhaugh et al.
CIRCULATION-HEART FAILURE (2020)
Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction
Thomas A. Gaziano et al.
JAMA CARDIOLOGY (2020)
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
Andrew P. Ambrosy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Piotr Ponikowski et al.
LANCET (2020)
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction
Stephen J. Greene et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial
Michael E. Nassif et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial
Brian P. Halliday et al.
LANCET (2019)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Medical Therapy for Heart Failure With Reduced Ejection Fraction
Stephen J. Greene et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States
Adam D. DeVore et al.
CIRCULATION-HEART FAILURE (2018)
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
Michael Bohm et al.
EUROPEAN HEART JOURNAL (2017)
Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial
G. Michael Felker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy
Naoki Okumura et al.
CIRCULATION-HEART FAILURE (2016)
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial
Orly Vardeny et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
Thomas A. Gaziano et al.
JAMA CARDIOLOGY (2016)
Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure
Adam D. DeVore et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)
Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure
Adam D. DeVore et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)
Patient-Accessible Tool for Shared Decision Making in Cardiovascular Primary Prevention Balancing Longevity Benefits Against Medication Disutility
Marianna Fontana et al.
CIRCULATION (2014)
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis
Richard W. Troughton et al.
EUROPEAN HEART JOURNAL (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Decision Making in Advanced Heart Failure A Scientific Statement From the American Heart Association
Larry A. Allen et al.
CIRCULATION (2012)
Pharmacogenetic targeting of drugs for heart failure
Michael R. Bristow
PHARMACOLOGY & THERAPEUTICS (2012)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Karl Swedberg et al.
LANCET (2010)
Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials
G. Michael Felker et al.
AMERICAN HEART JOURNAL (2009)
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
Marvin A. Konstam et al.
LANCET (2009)
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
AL Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
